Authors
Latest:
Dr Hannan on the Advantages of Stereotactic Radiation in Primary and Locally Advanced RCCRaquibul Hannan, MD, PhD, discusses the advantages of stereotactic radiation in primary or locally advanced renal cell carcinoma.
Latest:
Research on CAR T Therapy in Earlier Lines of TreatmentAmit Patel, BSc, MBBS, PhD, discusses currently ongoing clinical trials of CAR T-cell therapy in first- and second-line treatment settings and comments on potential developments on the horizon.
Latest:
Key Takeaways and Clinical Pearls in the Treatment of R/R ALLThe key opinion leaders provide concluding insights and essential recommendations regarding the management of relapsed/refractory acute lymphoblastic leukemia.
Latest:
Dr Abushahin on Biomarker Testing in mCRCLaith Abushahin, MD, discusses the evolution of targeted therapy for patients with metastatic colorectal cancer and the importance of biomarker testing in this patient population.
Latest:
Extending the Frontiers of Checkpoint Inhibition in Merkel Cell CarcinomaIn the treatment of unresectable or metastatic Merkel cell carcinoma, immune checkpoint inhibitors have activity and tolerability.
Latest:
Dr. Ahn on Choosing Between Treatment Options in CLLInhye Ahn, MD, physician, discusses choosing between treatment options in chronic lymphocytic leukemia.
Latest:
Dr Platzbecker on First-Line ATRA/ATO in High-Risk Acute Promyelocytic LeukemiaUwe Platzbecker, MD, discusses efficacy data with the combination of all-trans retinoic acid and arsenic trioxide in high-risk acute promyelocytic leukemia.
Latest:
Dr. Marabelle on Preliminary Findings With SO-C101 in Advanced Solid TumorsAurélien Marabelle, MD, PhD, discusses preliminary findings from a trial examining SO-C101 in patients with advanced solid tumors.
Latest:
Dr Chamie on the FDA Approval of N-803 Plus BCG for BCG-Unresponsive NMIBCKarim Chamie, MD, discusses the FDA approval of nogapendekin alfa plus BCG for patients with BCG-unresponsive non–muscle invasive bladder cancer.
Latest:
Dr Vaishampayan on Patient Considerations When Choosing Between FDA-Approved Therapies in nmCRPCUlka Nitin Vaishampayan, MBBS, discusses patient factors to consider when choosing between apalutamide, enzalutamide, and darolutamide for the treatment of patients with non-metastatic castration resistant prostate cancer.
Latest:
Dr. Ma on First-Line Treatment Considerations in Metastatic Pancreatic CancerWen Wee Ma, MBBS, discusses first-line treatment considerations in metastatic pancreatic cancer.
Latest:
Window of Opportunity Trials Are Needed for Novel Tissue Biomarker Analysis in Head and Neck CancersDrug development is a difficult and ever-changing process, with new agents being developed by industry and academic partners.
Latest:
Clinical Scenario and Perspectives on the Evolving Treatment Landscape in GVHDDr. Hannah Choe discusses a clinical scenario of a patient with GVHD who has progressed after multiple lines of treatment. She explores how the availability of CSF-1R inhibitors could fit into the evolving treatment landscape for managing this difficult-to-treat patient population. Dr. Choe provides her perspectives on the potential role and clinical implications of targeting this pathway as an emerging therapeutic approach for GVHD.
Latest:
Dr Merchán on the Future Treatment of Advanced RCCJaime R. Merchán, MD, discusses the future treatment of patients with advanced renal cell carcinoma.
Latest:
Future Treatment Landscape of AMLCorey S. Cutler, MD, MPH, FRCPC; Adam Bagg, MD; Alexander E. Perl, MD, MS; Eunice S. Wang, MD; and Harry P. Erba, MD, PhD, share closing thoughts and emerging therapies on the horizon for the treatment of AML.
Latest:
Dr Knight on Diagnosing and Managing Brain-Metastatic Prostate AdenocarcinomaJames Knight, MD, discusses a case study of a patient with brain-metastatic prostate adenocarcinoma.
Latest:
Leveraging BTK Inhibitors in Chronic Lymphocytic LeukemiaThe choice of BTK inhibitor regimen for patients with chronic lymphocytic leukemia must be tailored to the patient, taking into consideration their preferences and comorbidities, as well as potential treatment-related adverse effects.
Latest:
Key Takeaways For Treating Patients Diagnosed With CholangiocarcinomaProvider and patient perspectives on why patient education about FGFRi treatment-associated adverse events and how to manage them are is essential in helping patients maintain a good quality of life and stay on treatment.
Latest:
Dr. Planchard on the Benefit of Sunvozertinib in EGFR Exon 20–Mutated NSCLCDavid Planchard, MD, PhD, discusses the benefit of sunvozertinib in EGFR exon 20–mutated non–small cell lung cancer (NSCLC).
Latest:
Evolving Treatment Landscape of HER2+ Metastatic Breast CancerClosing out their discussion on novel therapies for HER2+ metastatic breast cancer, experts share excitement for future clinical trials and strategies.
Latest:
Dr. Kimmick on Selecting Adjuvant Therapy for Patients With HER2+ Breast CancerGretchen G. Kimmick, MD, MS, discusses selecting adjuvant therapy for patients with HER2-positive breast cancer.
Latest:
Dr Raje on the DREAMM-7 and DREAMM-8 Trials in Multiple MyelomaNoopur S. Raje, MD, and Yan Leyfman, MD, discuss the phase 3 DREAMM-7 and DREAMM-8 trials on OncLive News Network: On Location.
Latest:
Dr Davids on Treatment With Pirtobrutinib in CLL/SLL With/Without Prior BCL-2 Inhibitor ExposureMatthew S. Davids, MD, MMSc, discusses key efficacy results from 2 follow-up analyses of the phase 1/2 BRUIN trial evaluating pirtobrutinib.
Latest:
Dr. Mercado on Evolution of Biopsy Techniques in Lung CancerJorge M. Mercado, MD, discusses the evolution of biopsy techniques in patients with lung cancer.
Latest:
Dr. Labaki on Disparities in Mammography Screenings During the COVID-19 PandemicChris Labaki, MD, discusses racial disparities with regard to mammography screenings during the COVID-19 pandemic.
Latest:
Key Unmet Needs in Prostate Cancer ManagementBefore centering discussion on subsets of prostate cancer, panelists consider general challenges and unmet needs within the treatment landscape.
Latest:
Dr. Nair on Using Yoga to Improve Quality of Life in Patients Undergoing Breast Cancer TreatmentsNita Nair, MBBS, DNB, MCh, discusses research evaluating the role of yoga as a way to improve the quality of life of patients undergoing breast cancer treatments.
Latest:
Dr Philip on the Development of T-Cell Dysfunction in Liver Cancer and Melanoma Cell ModelsMary Philip, MD, PhD, discusses research on the key transcriptional and epigenetic programs that regulate CD8 T cell fate decisions in cancer models.
Latest:
Dr. Botta on the Diagnosis and Treatment of ESCCGregory Botta, MD, PhD, discusses the diagnosis and treatment of patients with esophageal squamous cell carcinoma.
.jpg?fit=crop&auto=format)
